The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) today announced that it has recommended six new medicines following its January 28-31 meetings.
The CHMP adopted a positive opinion for Ajovy (fremanezumab), from Israel’s Teva Pharmaceutical Industries (NYSE: TEVA), for the prophylaxis of migraine.
Vizimpro (dacomitinib), from US pharma giant Pfizer (NYSE: PF), received a positive opinion for the treatment of locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor activating mutations.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze